🇺🇸 FDA
Patent

US 12043843

Materials and methods for treatment of hemoglobinopathies

granted A61KA61K48/00A61P

Quick answer

US patent 12043843 (Materials and methods for treatment of hemoglobinopathies) held by Vertex Pharmaceuticals Incorporated expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K48/00, A61P, A61P7/00